STOCK TITAN
  1. Home
  2. News
  3. AWH

Aspira Women`s Health Inc - AWH STOCK NEWS

Welcome to our dedicated news page for Aspira Women`s Health (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aspira Women`s Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aspira Women`s Health's position in the market.

News
Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Rhea-AI Summary
Aspira Women’s Health Inc. announces a new agreement with Anthem Blue Cross in California for reimbursement coverage of its OvaSuite portfolio, impacting approximately 6 million lives. The agreement includes commercial, Medicare Advantage, and Medicaid coverage effective June 1, 2024, marking a significant milestone in Aspira's strategic focus on payer adoption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.93%
Tags
none
-
News
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Aspira Women’s Health Inc. reported a 15% increase in 2023 OvaSuite revenue to $9.2 million, with a 12% rise in volume. The company lowered cash utilization, held a successful conference call, and had various corporate highlights including raising $5.5 million and securing reimbursement agreements. Financially, product revenue grew to $9.2 million in 2023, gross profit margin improved to 57.5%, and operating cash usage decreased by 49% year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
earnings
-
News
Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
Rhea-AI Summary
Aspira Women’s Health Inc. will announce its financial results for the three months and year ended December 31, 2023, on March 28, 2024. The company, focused on developing gynecologic disease diagnostic tools, will hold a conference call at 8:30 am ET to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
earnings
News
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
Rhea-AI Summary
Aspira Women’s Health Inc. announced their participation in the MedInvest Biotech & Pharma Investor Conference in New York City on April 3-4, 2024. Investors can schedule one-on-one meetings with management. The presentation will be available for viewing on Aspira's IR website post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
News
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
Rhea-AI Summary
Aspira Women’s Health Inc. appoints Dr. Sandra Milligan as President and Dr. Todd Pappas as head of product development. Dr. Milligan brings 25+ years of experience in healthcare and pharmaceutical sectors, focusing on women's health. Dr. Pappas replaces Dr. Jody Berry, overseeing product development and academic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
management
-
News
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) will report financial results for Q4 2023 on March 28, 2024. The company focuses on developing diagnostic tools for gynecologic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
earnings
News
Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
Rhea-AI Summary
Aspira Women’s Health Inc. announces participation in The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference. The Company will present a corporate overview and be available for one-on-one meetings with investors. Date: March 1, 2024, Time: 9:30 am CST / 10:30 am EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
News
Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
Rhea-AI Summary
Aspira Women’s Health Inc. announces a late-breaking poster presentation at the 71st Annual Scientific Meeting for the Society for Reproductive Investigation. The presentation focuses on EndoCheckSM, a noninvasive diagnostic test for endometriosis, a common gynecologic disease affecting millions of women. The poster details a Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis, co-authored by Aspira’s R&D team and the Oxford Endometriosis Care and Research Centre. The presentation is a significant step towards launching a groundbreaking diagnostic tool for this debilitating disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
-
News
Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines
Rhea-AI Summary
Aspira Women’s Health Inc. signs a 5-year distribution agreement with Hi-Precision Laboratories, the largest medical laboratory in the Philippines, to market and distribute the OvaSuite portfolio in the country. The agreement includes royalties to Aspira for each test performed. This partnership aims to improve the detection of early-stage ovarian cancer in Filipino women, addressing the higher risk of ovarian cancer in the Philippines compared to other parts of the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
News
Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement
Rhea-AI Summary
Aspira Women’s Health Inc. announced a registered direct offering and concurrent private placement of 1,571,000 shares of its common stock at a combined purchase price of $3.50 per share to institutional investors and existing shareholders. CEO Nicole Sandford and certain existing shareholders will also participate in the purchase. The warrants will have exercise prices ranging from $4.00 to $4.13 per share, with expiration 5 years from the initial exercise date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
offering
Stock AWH logo
Aspira Women`s Health Inc

Nasdaq:AWH

AWH Rankings

#4839 Ranked by Market Cap
#3410 Ranked by Stock Gains
N/A Ranked by Dividends

AWH Stock Data

42.59M
9.36M
38.84%
9.09%
1.09%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Austin

About AWH

vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.